Clinical trial
Efficacy and Tolerability of Angeliq in Thai Women
NCT00185328 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00185328 |
|---|---|
| Title | Efficacy and Tolerability of Angeliq in Thai Women |
| Official title | A Multi-Center, Open-Label, Non-Comparative Study Investigating the Efficacy and Tolerability of Angeliq® in Postmenopausal Thai Women With Vasomotor Symptoms Over Three 28-Day Treatment Cycles |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Postmenopause |
| Intervention type | Drug |
| Interventions | Estradiol/DRSP (Angeliq, BAY86-4891) |
| Enrollment | 55 |
| Start date | Sep 1, 2005 |
| Completion | Dec 1, 2006 |
| First posted | Sep 16, 2005 |
| Last update posted | Dec 12, 2008 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: